Market News & Trends
Exostar & Taigle Partnership Delivers Solutions to Life Science & Healthcare Markets
Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, and Taigle mySignatureBook, a leading digital workflow provider in the…
Global Biosimilars Market Value Could Hit $55 Billion
The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth…
PharmaCyte Biotech Enters Into Research & Consulting Agreement
PharmaCyte Biotech, Inc. recently announced it has signed a major Research Services Agreement and an important Consulting Contract with the University of Technology Sydney (UTS)…
Protein Sciences Reports Topline Data for Flublok Quadrivalent
Protein Sciences Corporation recently announced topline data showing that Flublok Quadrivalent, the quadrivalent version of FDA-approved trivalent Flublok influenza vaccine, outperformed a traditional influenza vaccine…
Vaxon Biotech Granted Patent for New Cancer Vaccine Candidates
Vaxon Biotech recently announced it has been granted a new patent in Japan. This patent (JP application n°2012-502822) covers a series of optimized cryptic peptides…
Perle Bioscience’s Insulin Independence Revolutionary Phase III Trial
Perle Bioscience, Inc. recently announced enrollment for the Insulin Independence Trial (IIT). This trial is the first and only Phase III trial to test a…
Cristal Therapeutics Highlights Proprietary CriPec Nanomedicine Platform & Promising Data
Cristal Therapeutics recently announced the publication of three articles on CriPec-based nanomedicines in Nano Today, Journal of Controlled Release, and Biomaterials. The publications are co-authored…
Vaccinex Announces Initiation of Phase III Clinical Trial for Huntington's Disease
Vaccinex, Inc. recently announced it has initiated a Phase II clinical trial to assess the safety, tolerability, and efficacy of anti-semaphorin 4D antibody VX15/2503 (VX15)…
Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014
The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36 in 2014, with their combined…
Bristol-Myers Squibb Will Win Big with Melanoma Combination Immunotherapy
Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of immunotherapies…
SIGNiX & Exostar Partner to Deliver Secure, Compliant Digital Signature Solution to Life Science & Healthcare
Researchers, Clinical Trial Participants, Physicians and Others Can Access Cloud-Based Independent E-Signatures™ via the Exostar Life Sciences Identity Hub CHATTANOOGA, Tenn., June 18, 2015 –…
PlasmaTech Announces Name Change to Abeona Therapeutics; Reflects Broader Rare Disease Commitment
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, recently…
Emulate Announces Strategic Collaboration With Johnson & Johnson Innovation to Use Organs-on-Chips Platform
Emulate, Inc. recently announced that it recently formed a research collaboration with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson (Janssen), to…
Taiho & Servier Enter Into Exclusive License Agreement
Taiho Pharmaceutical Co., and Servier recently announced they have entered into an exclusive license agreement for the development and commercialization of TAS-102 (non-proprietary names: trifluridine…
PDC*line Pharma Receives Advanced-Therapy Medicinal Product Classification for New Class of Therapeutic Cancer Vaccines
PDC*line Pharma recently announced that PDC*vac, its new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic Cells (PDC*line), was granted Advanced-Therapy…
ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform
ONL Therapeutics, Inc. recently provided an update on the company’s ongoing drug development program to block the programmed cell death (apoptosis) of photoreceptors. Death of…
LDC to Collaborate With Johnson & Johnson to Identify & Accelerate Innovative Drug Candidates
The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate innovative drug candidates for the treatment and…
Recipharm Completes Acquisition; Broadens Development Capabilities
Recipharm recently announced that it has completed the acquisition of OnTarget Chemistry in Uppsala, Sweden. OnTarget Chemistry is a fast growing CRO company with a…
Pancreatic Cancer Treatment Pipeline Dominated by Early Stage Development
While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the…
Ajinomoto Althea Receives European GMP Certification for Commercial Aseptic Filling & Testing
Ajinomoto Althea, Inc. (Althea), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate…
